Company intelligence / Profile preview

MalarVx

Seattle, Washington, United States

Ownership: Private
Development stage: Other

Overview

Preclinical studies in mouse models show that the prime-and-trap vaccine approach—using repRNA/LION nanocarrier and radiation-attenuated sporozoites—induces robust, durable immune responses and >80% sterile protection in accelerated dosing regimens. Mice challenged after same-day immunization showed 90% sterile protection at three weeks and 70% at two months. MalarVx is entering late-stage preclinical and clinical development.

Therapeutic areas: Infectious Diseases
Modalities: Self-amplifying replicon RNA (repRNA)VaccineLipid nanoparticle (LION™)Radiation-attenuated whole organism parasite (Radiation Attenuated Sporozoite)Genetically attenuated parasite
Industry: Biotech

Drug pipeline

4 assets

MVX-IVS

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

HDT Bio (for LION™ platform and repRNA technology)

Beyond the preview

Go deeper on MalarVx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MalarVx.

Explore the full profile